Progyny sees Q4 adjusted EPS 31c-35c, consensus 14c

Sees Q4 revenue $266.2M-$281.2M, consensus $292.68M. “As the fourth quarter has begun, the rate of utilization remains healthy and we’re seeing members consume more treatments as compared to the third quarter. Nonetheless, given the unexpected variability we’ve seen this year, we believe the prudent approach is to guide with the expectation this variability continues. Accordingly, we are revising our expectations for the balance of the year,” said Anevski.